16: How the quality culture impacts GMP activity
PharmaLex Talks22 Helmi 2023

16: How the quality culture impacts GMP activity

A strong quality culture in the biopharmaceutical industry is one in which all participants in the organization understand patient safety and how their roles impact patient safety risks. It is one where decisions are prioritized based on patient safety first. From a GMP perspective, that means not only abiding by the formal law but knowing the applicable current best practices, understanding the risks a company’s processes and products pose to patients and implementing effective quality risk management practices.

About the speaker:
Londa Ritchey is Quality Director with the Quality Management and Compliance group at PharmaLex.

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(37)

37: Optimizing revenue from mature products

37: Optimizing revenue from mature products

We talk with Paula King, Director, Regulatory Affairs at PharmaLex to better understand the growing trend toward regulatory outsourcing, particularly of the mature product portfolio. Hear how leading ...

18 Heinä 20259min

36: What’s happening with eCTD 4.0: New and future developments

36: What’s happening with eCTD 4.0: New and future developments

Join Karl-Heinz Loebel, Director, Regulatory Informatics & Operations at PharmaLex, as he discusses current progress of eCTD 4.0. Ten years after the eCTD 4.0 standard became available for submissions...

18 Heinä 202520min

35: Challenges and best practices for managing local pharmacovigilance activities

35: Challenges and best practices for managing local pharmacovigilance activities

In this episode of the PharmaLex Talks Podcast, sits down with Alex Brenchat, Vice President of Local Affiliate Pharmacovigilance Services at PharmaLex, a Cencora company. Together, they explore the c...

9 Touko 202512min

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

34: Environmental Risk Assessment and its growing importance in the German Pharma Strategy

Join Angela-Vogt Eisele, Associate Director Scientific Affairs at PharmaLex, a Cencora company for this podcast, where she shares her expertise in Environmental Risk Assessment and its growing importa...

14 Huhti 202520min

33: Finding the best approach to manage sterility assurance

33: Finding the best approach to manage sterility assurance

Join PharmaLex's Patrick Nieuwenhuizen for this podcast, where he shares his expertise in sterility assurance and how manufacturers can demonstrate that the finished product is sterile through a holis...

27 Tammi 202515min

32: Commercialization Readiness

32: Commercialization Readiness

Pharmaceutical companies new to the EU market must navigate complex and varying commercialization requirements. The podcast highlights key steps for commercialization readiness in Europe, focusing on ...

4 Marras 202413min

31: Key Steps for Site Inspection Readiness

31: Key Steps for Site Inspection Readiness

Louise Uí Fhatharta bio Quality professional with over 20 years’ experience in Microbiology, Quality Control and Quality Assurance roles in the Pharmaceutical Industry including Sterile Fill Finish a...

27 Kesä 202417min

30: CSS Overview

30: CSS Overview

A contamination control strategy (CCS) is integral to Annex 1 and is fundamentally about patient safety and identifying and avoiding contamination pathways. Manufacturers are expected to implement a C...

9 Touko 202414min

Suosittua kategoriassa Politiikka ja uutiset

uutiscast
aikalisa
politiikan-puskaradio
rss-ootsa-kuullut-tasta
ootsa-kuullut-tasta-2
rss-vaalirankkurit-podcast
tervo-halme
otetaan-yhdet
rss-podme-livebox
viisupodi
et-sa-noin-voi-sanoo-esittaa
rss-pinnalla
rss-asiastudio
rss-girls-finish-f1rst
linda-maria
rss-raha-talous-ja-politiikka
rss-ulkopoditiikkaa
rikosmyytit
the-ulkopolitist
rss-polikulaari-pitka-kiekko-ja-muut-ts-podcastit